Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.55 |
| ▸ | KDM6B | O15054 | 1/20 | 0.55 |
| ▸ | KDM5C | P41229 | 1/20 | 0.55 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.55 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16929773 | 0.98 | KDM4E (0.54) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| Hydrochloric Acid SCHEMBL28377156 | 0.98 | KDM4E (0.54) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL10263738 | 0.85 | KDM4E (0.57) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL348975 | 0.85 | KDM4C (0.57) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL31320065 | 0.85 | KDM4E (0.57) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL30740808 | 0.85 | KDM4C (0.57) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL3872835 | 0.84 | JMJD6 (0.53) | KDM4CKDM5CJMJD6KDM5BKDM5A | |
| SCHEMBL1007105 | 0.83 | KDM4E (0.55) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL22005801 | 0.83 | KDM5C (0.55) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL29700409 | 0.83 | KDM4E (0.55) | KDM4EKDM4CKDM6BKDM5CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250161468-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20240390507-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| CN-114521196-A | Bifunctional group degradation agent and use method thereof | 诺华股份有限公司 | 2022-05-20 | — | — | CN | disclosed |
| US-11197933-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-1476449-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004064836-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003070732-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-0161737-B1 | ELECTROCHEMICAL REDUCTIONS OF CYANOPYRIDINE BASES | REILLY INDUSTRIES, INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| EP-0161737-A1 | Electrochemical reductions of cyanopyridine bases | REILLY INDUSTRIES, INC. (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4482437-A | Electrochemical reductions of cyanopyridine bases | REILLY TAR & CHEMICAL CORP. (US) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197933-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRM1, OPRK1, OPRL1 | KDM4E 1929/4885KDM4C 2145/4885KDM6B 872/4885 |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | KDM4E 2112/4885KDM4C 2874/4885KDM6B 1699/4885 |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | KDM4E 3522/4885KDM4C 3141/4885KDM6B 3843/4885 |
| US-20250161468-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRL1 | KDM4E 1929/4885KDM4C 2145/4885KDM6B 872/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | KDM4E 1649/4885KDM4C 1409/4885KDM6B 477/4885 |
| US-20240390507-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRL1 | KDM4E 1929/4885KDM4C 2145/4885KDM6B 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.